Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity

European Journal of Medical Research

Volumn 15, Issue 2, 2010, Pages 81-83

  Ortu, F ^a   Weimer, L E ^b   Floridia, Marco ^b   Manconi, P E ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antiretroviral treatment; Chronic active hepatitis; Emtricitabine; HIV HCV; Raltegravir; Tenofovir

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; INTERFERON; LAMIVUDINE; NEVIRAPINE; PEGINTERFERON ALPHA2A; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR PLUS RITONAVIR; IMMUNOGLOBULIN G ANTIBODY; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE SEVERITY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER TOXICITY; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROLITHIASIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING; DRUG OVERDOSE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; LIVER FIBROSIS; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RASH; REVIEW; TREATMENT DURATION; VIROLOGICAL RESPONSE;

EID: 77949594437     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-2-81     Document Type: Article

References (14)

1. Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol. 2009;15:3713-24.
2. Vogel M, Rockstroh JK. Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS. 2007;2:306-13.
3. Walker UA. Antiretroviral therapy-induced liver alterations. Curr Opin HIV AIDS. 2007;2:293-8.
4. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004 Nov 19;18(17):2277-84.
5. Pineda JA, Pérez-Elías MJ, Peña JM, Luque I, Rodríguez-Alcantara F. Fosamprenavir Expanded Access Program Group. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin Trials. 2008; 9:309-13.
6. Jevtovic Dj, Ranin J, Salemovic D, et al. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART. Biomed Pharmacother. 2008;62:21-5.
7. Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, Lozano F, Macías J; Liverey Study Investigator Team. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother. 2008;61(4):925-32.
8. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518. in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007; 369:1261-1269.
9. Croxtall JD, Keam SJ. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs. 2009;69:1059-75.
10. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 24:339-54.
11. Núñez MJ, Martín-Carbonero L, Moreno V, Valencia E, Garcia-Samaniego J, Castillo JG, Barreiro P, González-Lahoz J, Soriano V. Impact of antiretroviral treatment-re-lated toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses. 2006;22:825-9.
12. Palacios R, Vergara S, Rivero A, Aguilar I, Macías J, Camacho A, Lozano F, García-Lázaro M, Pineda JA, Torre-Cisneros J, Marquez M, Santos J. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials. 2006;7:319-23.
13. Meraviglia P, Schiavini M, Castagna A, Viganò P, Bini T, Landonio S, Danise A, Moioli MC, Angeli E, Bongiovanni M, Hasson H, Duca P, Cargnel A. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med. 2004;5:334-43.
14. Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother. 2009 Dec 23. [Epub ahead of print]